aTyr Pharma Inc (LIFE)
1.60
0.00 (0.00%)
USD |
NASDAQ |
Apr 25, 10:57
aTyr Pharma Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.0952 |
| June 30, 2020 | 0.1378 |
| March 31, 2020 | 0.163 |
| December 31, 2019 | 0.4124 |
| September 30, 2019 | 0.3959 |
| June 30, 2019 | 0.4108 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.4124
Maximum
Dec 2019
0.0897
Average
--
Median
Dec 2020
Debt to Equity Ratio Benchmarks
| Vaxart Inc | 0.00 |
| Allogene Therapeutics Inc | 0.00 |
| AIM ImmunoTech Inc | 0.00 |
| Protalix BioTherapeutics Inc | 0.6033 |
| Armata Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 120.65M |
| Total Liabilities (Quarterly) | 30.18M |
| Shareholders Equity (Quarterly) | 90.66M |